Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation
© 2017 The British Pharmacological Society..
AIMS: MicroRNAs (miRNAs) may be useful biomarkers of rejection and allograft outcome in kidney transplantation. Elevated urinary CXCL10 levels have been associated with acute rejection (AR) and may predict allograft failure. We examined the correlation of miRNA, CXCL10 levels and immunosuppressive drug exposure with AR and graft function in kidney transplant recipients.
METHODS: Eighty de novo kidney transplant recipients were recruited from four European centres. All patients received tacrolimus, mycophenolate mofetil, and methylprednisolone. Urinary pellet expression of miR-142-3p, miR-210-3p and miR-155-5p was assessed by quantitative real-time polymerase chain reaction and urinary CXCL10 levels by enzyme-linked immunosorbent assay at the 1st week and the 1st , 2nd , 3rd and 6th months post-transplantation.
RESULTS: Eight patients experienced AR. Before and during AR, patients showed a significant increase of urinary miR-142-3p, miR-155-5p and CXCL10 levels and a decrease of miR-210-3p levels. Receiver operating characteristic curve analysis showed that miR-155-5p (area under the curve = 0.875; P = 0.046) and CXCL10 (area under the curve = 0.865; P = 0.029) had excellent capacity to discriminate between rejectors and nonrejectors. The optimal cut-off values for the prognosis of AR were 0.51, with 85% sensitivity and 86% specificity for miR-155-5p and 84.73 pg ml-1 , with 84% sensitivity and 80% specificity for CXCL10. miR-155-5p and CXCL10 levels correlated with glomerular filtration rate. Levels of both biomarkers normalized after recovery of graft function.
CONCLUSIONS: The regular early post-transplantation monitoring of urinary miR-155-5p and CXCL10 can help in the prognosis of AR and graft dysfunction. Large prospective randomized multicentre trials are warranted to refine our cut-off values and validate the clinical usefulness of these biomarkers.
| Errataetall: |
CommentIn: Br J Clin Pharmacol. 2017 Dec;83(12):2602-2604. - PMID 28880407 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 83(2017), 12 vom: 17. Dez., Seite 2636-2650 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Millán, Olga [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.01.2018 Date Revised 09.01.2021 published: Print-Electronic CommentIn: Br J Clin Pharmacol. 2017 Dec;83(12):2602-2604. - PMID 28880407 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.13399 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM275519848 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM275519848 | ||
| 003 | DE-627 | ||
| 005 | 20231225005848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.13399 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0918.xml |
| 035 | |a (DE-627)NLM275519848 | ||
| 035 | |a (NLM)28880456 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Millán, Olga |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2018 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Clin Pharmacol. 2017 Dec;83(12):2602-2604. - PMID 28880407 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 The British Pharmacological Society. | ||
| 520 | |a AIMS: MicroRNAs (miRNAs) may be useful biomarkers of rejection and allograft outcome in kidney transplantation. Elevated urinary CXCL10 levels have been associated with acute rejection (AR) and may predict allograft failure. We examined the correlation of miRNA, CXCL10 levels and immunosuppressive drug exposure with AR and graft function in kidney transplant recipients | ||
| 520 | |a METHODS: Eighty de novo kidney transplant recipients were recruited from four European centres. All patients received tacrolimus, mycophenolate mofetil, and methylprednisolone. Urinary pellet expression of miR-142-3p, miR-210-3p and miR-155-5p was assessed by quantitative real-time polymerase chain reaction and urinary CXCL10 levels by enzyme-linked immunosorbent assay at the 1st week and the 1st , 2nd , 3rd and 6th months post-transplantation | ||
| 520 | |a RESULTS: Eight patients experienced AR. Before and during AR, patients showed a significant increase of urinary miR-142-3p, miR-155-5p and CXCL10 levels and a decrease of miR-210-3p levels. Receiver operating characteristic curve analysis showed that miR-155-5p (area under the curve = 0.875; P = 0.046) and CXCL10 (area under the curve = 0.865; P = 0.029) had excellent capacity to discriminate between rejectors and nonrejectors. The optimal cut-off values for the prognosis of AR were 0.51, with 85% sensitivity and 86% specificity for miR-155-5p and 84.73 pg ml-1 , with 84% sensitivity and 80% specificity for CXCL10. miR-155-5p and CXCL10 levels correlated with glomerular filtration rate. Levels of both biomarkers normalized after recovery of graft function | ||
| 520 | |a CONCLUSIONS: The regular early post-transplantation monitoring of urinary miR-155-5p and CXCL10 can help in the prognosis of AR and graft dysfunction. Large prospective randomized multicentre trials are warranted to refine our cut-off values and validate the clinical usefulness of these biomarkers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CXCL10 | |
| 650 | 4 | |a acute rejection | |
| 650 | 4 | |a drug exposure | |
| 650 | 4 | |a kidney graft function | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a miR-142-3p | |
| 650 | 4 | |a miR-155-5p | |
| 650 | 4 | |a miR-210-3p | |
| 650 | 4 | |a microRNAs | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a CXCL10 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CXCL10 |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a MIRN155 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 700 | 1 | |a Budde, Klemens |e verfasserin |4 aut | |
| 700 | 1 | |a Sommerer, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Aliart, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Rissling, Olesja |e verfasserin |4 aut | |
| 700 | 1 | |a Bardaji, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Matz, Maaren |e verfasserin |4 aut | |
| 700 | 1 | |a Zeier, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Guirado, Lluis |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Mercè |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 83(2017), 12 vom: 17. Dez., Seite 2636-2650 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2017 |g number:12 |g day:17 |g month:12 |g pages:2636-2650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.13399 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2017 |e 12 |b 17 |c 12 |h 2636-2650 | ||